Stemcells, Inc. Announces First High-Dose Patient Transplanted in Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
12 sept. 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced dosing of the first high-dose patient in the Company's Phase I/II clinical trial in dry age-related...
StemCells, Inc. Publishes Comprehensive Review of Results From HuCNS-SC Clinical Trials
09 sept. 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Sept. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of a comprehensive overview describing the therapeutic potential and results from early...
StemCells, Inc. Reports Second Quarter 2013 Financial Results and Provides Business Update
07 août 2013 16h05 HE
|
StemCells, Inc.
NEWARK, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
StemCells, Inc. Announces Webcast to Discuss Second Quarter 2013 Financial Results and Business Update
05 août 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Aug. 5, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
StemCells, Inc. Presents Two-Year Pelizaeus-Merzbacher Disease (PMD) Data Suggesting Departure From Natural History of the Disease
02 août 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Aug. 2, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today presented data which show that two years after transplantation of the Company's proprietary HuCNS-SC® cells...
StemCells, Inc. Launches Alzheimer's Disease Program Supported by California Institute for Regenerative Medicine
30 juil. 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., July 30, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has formally launched its Alzheimer's disease program, which is being supported by the...
StemCells, Inc. Added to Russell Microcap Index
01 juil. 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced its addition to the Russell Microcap Index following Russell Investments' reconstitution of its...
StemCells, Inc. Strengthens Product Development Team and Appoints Executive to Focus on Scientific and Strategic Alliances
10 juin 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced key hires to strengthen its product development capabilities and announced the creation of a new...
StemCells, Inc. Secures $30 Million Financing Commitment From Lincoln Park Capital
04 juin 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., June 4, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
StemCells, Inc.'s Spinal Cord Injury Trial Approved by Health Canada
03 juin 2013 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Health Canada has authorized the Company to expand its Phase I/II clinical trial for chronic spinal...